|
|
245 First St., Sixteenth Floor
Cambridge, MA 02142 USA
phone:617-301-7000
fax:617-301-7010
|
|
| Symbol |
CRXX |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.combinatorx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| A portfolio of product candidates targeting multiple immuno-inflammatory diseases and cancer. |
|
| Management |
| Alexis Borisy, A.M., President and CEO, Founder; Robert Forrester, Executive Vice President, Chief Financial Officer; Daniel Grau, M.Phil., Chief Operating Officer; Lynn G. Baird, Ph. D, Senior Vice President, Regulatory, Quality and Clinical Operations; Jason F. Cole, Esq., Senior Vice President, General Counsel; Curtis T. Keith, Ph.D., Senior Vice President; Research, Founder |
| |
|
|
|
|
|
|
|
| Keywords |
| new drugs, synergistic combinations, multiple immuno-inflammatory diseases, cancer. |
|
|
|
| Description |
|
CombinatoRx develops new drugs built from synergistic combinations of approved drugs. In less than five years, they have discovered and advanced into clinical trials a portfolio of seven product candidates targeting multiple immuno-inflammatory diseases and cancer. |
|
|
| Strategy |
The total investment, including development of their proprietary screening technology, thus far has been less than $50 million.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
